Tae Hyun  Hwang,  PhD

Tae Hyun Hwang, PhD

Assistant Staff

Lerner Research Institute, 9500 Euclid Avenue, Cleveland, Ohio 44195
Location: JJN3-326

Phone: (216) 442-5565

 

My research focuses on developing novel machine learning, artificial intelligence (AI) and computational/bioinformatics algorithms and tools to gain new insights about the genetic/phenotypic variants of human disease.

I am particularly interested in developing new machine learning and AI algorithms and bioinformatics approaches to integrate large-scale genomic, single cell sequencing, genetics, phenotypic, interactome (e.g. protein-protein interaction networks) networks, image and clinical data including electronic health records (EHR) to discover the genetic variants that might be used clinically to guide therapy decisions.

https://www.hwanglab.org

Lay Summary

My research is focused on developing novel machine learning and artificial intelligence algorithms that ultimately help to treat patients with disease.


1. Sunho Park, Hongming Xu, Tae Hyun Hwang, Gaussian Process Based Heteroscedastic Noise Modeling for Tumor Mutation Burden Prediction from Whole Slide Images, bioRxiv, 2019 February 19. doi: 10.1101/554261

 

2. Hongming Xu, Sunho Park, Sung Hak Lee, Tae Hyun Hwang , Using transfer learning on whole slide images to predict tumor mutational burden in bladder cancer patients, bioRxiv, 2019 February 19. doi: 10.1101/554527 

 

3. Rubina Tuladhar, Yunku Yeu, John Tyler Piazza, Zhen Tan, Jean Rene Clemenceau, Xiaofeng Wu, Quinn Barrett, Jeremiah Herbert, David H. Mathews, James Kim, Tae Hyun Hwang*, Lawrence Lum*, CRISPR/Cas9-based mutagenesis frequently provokes on-target mRNA misregulation, doi: https://doi.org/10.1101/583138

(*corresponding author)

 

4. Kenneth Chen, Woo Sun Kwon, Jiwoong Kim, Su Jin Heo, Hyo Song Kim, Hyo Ki Kim, Soo Hee Kim, Won Suk Lee, Hyun Cheol Chung, Sun Young Rha, and Tae Hyun Hwang*.,

A novel TP53-KPNA3 translocation defines a de novo treatment-resistant clone in osteosarcoma,

Molecular Case Studies, 2016 September;2(5):a000992. doi: 10.1101/mcs.a000992.

(*corresponding author)

 

5. Sunho Park, Seung-Jun Kim, Donghyeon Yu, Samuel Pena-Llopis, Jianjiong Gao,J in Suk Park, Beibei Chen, Jessie Norris, Xinlei Wang, Min Chen, Minsoo Kim,Jeongsik Yong, Zabi Wardak, Kevin Choe, Michael Story, Timothy Starr, Jae-Ho Cheong and Tae Hyun Hwang*.,

An integrative somatic mutation analysis to identify pathways linked with survival outcomes across 19 cancer types,

Bioinformatics, 2016 Jun 1; 3(11): 1643-1651. doi: 10.1093/bioinformatics/btv692

(* corresponding author)

 

6. Wenfang Chen, Haley Hill, Alana Christie, Min Soo Kim, Eboni Holloman, Andrea Pavia-Jimenez, Farrah Homayoun, Yuanqing Ma, Nirav Patel, Paul Yell, Guiyang Hao, Qurratulain Yousuf, Allison Joyce, Ivan Pedrosa, Heather Geiger, He Zhang, Jenny Chang, Kevin H. Gardner, Richard K. Bruick, Catherine Reeves, Tae Hyun Hwang, Kevin Courtney, Eugene Frenkel, Xiankai Sun, Naseem Zojwalla, Tai Wong, James P. Rizzi, Eli M. Wallace, John A. Josey, Yang Xie, Xian-Jin Xie, Payal Kapur, Renée M. McKay & James Brugarolas.,

Targeting Renal Cell Carcinoma with a HIF-2 antagonist,

Nature, 2016 September 5. doi: 10.1038/nature19796

 

7. Vural Tagal, Shuguang Wei, Wei Zhang, Rolf A. Brekken, Bruce A. Posner, Michael Peyton, Luc Girard, Tae Hyun Hwang, David A. Wheeler, John D. Minna, Michael A. White, Adi F. Gazdar, and Michael G. Roth.,

SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers,

Nature Communication, 2017 January 19;8:14098. doi: 10.1038/ncomms14098

 

8. Xiuxing Wang, Kailin Yang, Qi Xie, Qiulian Wu, Stephen C Mack, Yu Shi, Leo J Y Kim, Briana C Prager, William A Flavahan, Xiaojing Liu, Meromit Singer, Christopher G Hubert, Tyler E Miller, Wenchao Zhou, Zhi Huang, Xiaoguang Fang, Aviv Regev, Mario L Suvà, Tae Hyun Hwang, Jason W Locasale, Shideng Bao & Jeremy N Ric.,

Purine synthesis promotes maintenance of brain tumor initiating cells in glioma,

Nature Neuroscience, 2017 Mar 27. doi: 10.1038/nn.4537

 

9. Xuxu Sun, Sam C. Wang, Yonglong Wei, Xin Luo, Yuemeng Jia, Lin Li, Purva Gopal, Min Zhu, Ibrahim Nassour, Jen-Chieh Chuang, Thomas Maples, Cemre Celen, Liem H. Nguyen, Linwei Wu, Shunjun Fu, Weiping Li, Lijian Hui, Feng Tian, Yuan Ji, Shuyuan Zhang, Mahsa Sorouri, Tae Hyun Hwang, Lynda Letzig, Laura James, Zixi Wang, Adam C. Yopp, Amit G. Singal, Hao Zhu, Arid1a Has Context-Dependent Oncogenic and Tumor Suppressor Functions in Liver Cancer,

Cancer Cell, 2017 November 13;32(5):574-589.e6., doi: 10.1016/j.ccell.2017.12.011

 

10. Elizabeth A. McMillan, Caroline H. Diep, Saurabh Mendiratta, Myung-Jeon Ryu, Jean R. Clemenceau, Rachel M. Vaden, Kyle R. Covington, Michael Peyton, Kenneth Huffman, Xiaofeng Wu, Luc Girard, Ju-Hwa Kim, Yeojin Sung, Pei-Hsaun Chen, Joo Young Lee, Jordan Hanson, Yunku Yeu, Sunho Park, Jessica Sudderth, Christopher DeSevo,Donna M. Muzny, HarshaVardhan Doddapaneni, Richard A. Gibbs, Tae Hyun Hwang, John V. Heymach, Ignacio Wistuba, Kevin R. Coombes, Noelle S. Williams, David A. Wheeler, John B. MacMillan, John D. Minna, Ralph J. Deberardinis, Michael G. Roth, Bruce A. Posner, Hyunseok Kim, Michael A. White, Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer,

Cell, 2018 May 3; 173(4):864-878. doi: 10.1016/j.cell.2018.03.028.


05/06/2020 |  

Unraveling the Genetic Underpinnings of Gastric Cancer in Hispanic/Latino Patients

A collaborative team led by Lerner Research Institute and University of Texas Southwestern Medical Center researchers have uncovered genetic susceptibilities that put Hispanic/Latino patients at greater risk for developing gastric cancer than African American, Asian and White patients.




03/24/2020 |  

Department of Defense Awards $2.4M for Bladder Cancer Immunotherapy Research

Cleveland Clinic is one of the highest volume centers of excellence for bladder cancer research and care in the nation. With a new $2.4 million Translational Team Science Award from the Department of Defense (DoD), physician-scientist and project lead Omar Mian, MD, PhD—as well as partnering investigators Shilpa Gupta, MD, and Tae Hyun Hwang, PhD, and a team of talented collaborators—look to not only bolster Cleveland Clinic’s bladder cancer program, but also its rapidly expanding portfolio of immuno-oncology research.